Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adherence to Treat-to-Target Management in RA

Publish date:: October 7, 2019

In a large international cohort, lack of adherence to treat-to-target (T2T) in rheumatoid arthritis (RA) was evident in a large proportion despite being a protocol requirement. Patients with RA from 10 countries starting or changing conventional synthetic disease-modifying anti-rheumatic (csDMARDs) drugs, or starting tumor necrosis factor inhibitor (TNFi), were followed for 2 years in the RA BIODAM cohort. Participating physicians were required per-protocol to adhere to T2T strategy. Among the findings:

571 patients were recruited and 439 completed 2-year follow-up.
Failure adherence to T2T low-disease activity (T2T-LDA) was noted in 40.5% of visits.
High number of comorbidities, smoking, and high number of tender joints were independently associated with failure to implement T2T.

Citation:

Sepriano A, et al. Adherence to treat-to-target management in rheumatoid arthritis and associated factors: Data from the international RA BIODAM cohort. J Rheumatol. [Published online ahead of print September 15, 2019. doi: 10.3899/jrheum.190303.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Rheumatoid Arthritis

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Tocilizumab, methotrexate combo equals tocilizumab alone for preventing progression,

Biomarker-based prognostic score identifies cardiovascular risk in RA,

Early life exposure to famine raises risk of RA in adulthood,